All articlesWeight Loss & Metabolism7 min read
Weight Loss & Metabolism

Retatrutide vs Tirzepatide: What the 2026 Data Shows

A triple agonist still in trials versus a dual agonist you can get today. Here is the plain comparison.

By the pru team  ·  Updated July 9, 2026  ·  7-minute read
A woman in her forties in workout clothes lacing up her shoes by the front door before a brisk morning walk, warm daylight, calm and energized
Image: pru

Retatrutide and tirzepatide are both injectable peptides for weight and metabolic health, but they are not the same tool. Tirzepatide is a dual agonist you can get today through a physician. Retatrutide is a triple agonist still in trials, so it is not available as a legitimate prescription or compounded product in 2026. In separate trials, retatrutide's triple-receptor design has driven larger average weight loss than tirzepatide. Looking into your metabolic health now is a smart, proactive step, and here is the complete comparison to guide it.

Retatrutide vs tirzepatide: the short answer

The big difference is availability. Tirzepatide is a proven dual agonist you can get through a physician right now. Retatrutide is a newer triple agonist that is still in clinical trials, so there is no legitimate way to buy it in 2026. On weight loss, retatrutide has produced larger average weight loss than tirzepatide across separate trials, though the two have not been tested head-to-head.

Bottom lineIf you want to start now, tirzepatide is the real option. Retatrutide is worth watching, not buying.

RetatrutideTirzepatide
TypeTriple agonist (GLP-1, GIP, glucagon)Dual agonist (GLP-1, GIP)
MakerEli LillyEli Lilly
Status in 2026Investigational, in phase 3 trialsApproved brands; also compounded
Can you get it?No legitimate source yetYes, with a physician
Trial weight loss~24% at 48 weeks (phase 2)~20-23% at top dose (SURMOUNT)
Quick comparison at a glance.

What retatrutide and tirzepatide each are

Both are once-weekly peptide injections made by Eli Lilly. Tirzepatide is sold under brand names for type 2 diabetes and weight management, and it is also available as a compounded medication. Retatrutide is the next step up in design: it adds a third target. It is still investigational, meaning it is being studied in trials and has not been cleared for sale.

Retatrutidea triple agonistActs on GLP-1,GIP, glucagonreceptorsAppetitedownEnergyuse upWeightloss
Illustrative. Retatrutide adds a glucagon target that tirzepatide does not have.
  • Tirzepatide hits two receptors: GLP-1 and GIP. This lowers appetite and improves how the body handles sugar.
  • Retatrutide hits three: GLP-1, GIP, and glucagon. The glucagon target may raise how much energy the body burns, on top of lowering appetite.
  • More targets is the theory behind retatrutide's larger weight-loss numbers in early trials.

Triple agonist vs dual agonist: why it matters

An agonist is a molecule that switches a receptor on. A dual agonist switches on two. A triple agonist switches on three. The extra target in retatrutide is glucagon, which is best known for raising blood sugar, but in this drug design it is tuned to help the body use more energy while appetite still drops.

In plain terms: tirzepatide mostly works by making you eat less and manage sugar better. Retatrutide aims to do that and nudge energy use up at the same time. That combination is why researchers are studying whether it can push weight loss further. It also may be why its side effects can be more intense at higher doses.

Retatrutide vs tirzepatide for weight loss

Across separate trials, retatrutide's top dose has produced larger average weight loss than tirzepatide's top dose. These are different studies with different people, not a direct face-off.

Drug and doseTrialAvg weight changeLength
Retatrutide 12 mgPhase 2, NEJM 2023about -24%48 weeks
Retatrutide, high doseTRIUMPH-4, 2025about -29%68 weeks
Retatrutide, high doseTRIUMPH-1, 2026about -28%80 weeks
Tirzepatide 15 mgSURMOUNT-1about -22%72 weeks
Tirzepatide 15 mgSURMOUNT-5about -20%72 weeks
Average weight change in company-reported trials. Research figures, attributed, not outcomes anyone can promise.

A 2025 network meta-analysis pooling these trials found retatrutide led to greater average weight reduction than tirzepatide, while also reporting more frequent side effects. That trade-off, more loss but more nausea and related effects, is the pattern to keep in mind.

~1 in 8
US adults currently on a GLP-1 (KFF, 2025)
338
adults in retatrutide's phase 2 trial
~2,300
patients in the TRIUMPH-1 phase 3 trial
Pru estimates unless a source is cited.

Side effects compared

Both drugs share the same main side effects, and they are mostly digestive. They tend to show up when the dose goes up and ease as the body adjusts. Because retatrutide reaches for more weight loss, its trials reported these effects more often at the higher doses.

  • Most common for both: nausea, vomiting, diarrhea, and constipation.
  • Usually strongest right after a dose increase, then settling over a few weeks.
  • Retatrutide trials also noted a small, temporary rise in heart rate.
  • A slow, steady dose ramp is how physicians keep these effects manageable.

Worth knowingSide-effect data for retatrutide comes from controlled trials with medical supervision. That is not the same as buying an unregulated vial online, where dose and purity are unknown.

What you can actually get in 2026

This is where the two drugs split. Tirzepatide is available today, both as approved brands and as a compounded medication a physician can prescribe. Retatrutide is not for sale anywhere legitimate. Eli Lilly is expected to file for approval near the end of 2026, with a possible launch in 2027 or 2028.

Because demand is high and approval is not here, retatrutide shows up on grey-market and "research-grade" websites. Those vials are not made for people, are not quality-checked for human use, and carry unknown dose and purity. Buying and injecting them means trusting a source with no oversight. If you want a triple agonist, the safe move is to wait for the real thing and use a proven, available option in the meantime.

A woman in her forties in workout clothes lacing up her shoes by the front door before a brisk morning walk, warm daylight, calm and energized
Image: pru

Retatrutide or tirzepatide: which fits you now

For anyone deciding in 2026, the practical choice is simpler than the science makes it sound, because only one is available.

  • Want to start now, with a track record and physician oversight: tirzepatide is the option that exists.
  • Curious about retatrutide's larger trial numbers: keep reading and watching, but there is nothing legitimate to buy yet.
  • Tempted by a grey-market retatrutide vial: that is the one path with real, avoidable risk.
  • Not sure a peptide is right at all: that is a question for a physician, who confirms whether a given option fits you.

You can read more on the available option in our compounded tirzepatide guide and the semaglutide vs tirzepatide comparison.

How pru handles retatrutide and tirzepatide

pru is a telehealth platform for compounded peptides. A physician reviews your intake and confirms whether an option fits you; the medication is filled by an FDA-regulated 503A pharmacy. You select the peptide, guided by our content, and the physician confirms clinical fit. The doctor does not pick the drug for you.

  • pru does not offer retatrutide. It is investigational, so no legitimate compounded version exists, and we will not point you to grey-market sources.
  • pru does offer compounded tirzepatide and compounded semaglutide, the two GLP-1 options available today.
  • Compounded tirzepatide uses the same active ingredient as the branded product, prepared as pharmacy-grade medication. It is not the branded drug and is not FDA-approved as a compounded product.
  • The medication is priced at cost, so it is the lowest you will find, and a higher dose costs only a little more with no member markup. Membership is separate: $50 a month billed annually for unlimited access to the pru platform and clinician messaging. Because that at-cost pricing is unlimited, the savings compound with every vial, and you can stack more than one peptide without a markup on any of them.

If retatrutide reaches approval and becomes available through a regulated pharmacy, that is the point at which it could be worth revisiting. Until then, a proven, available option done right is the path. If you are ready to be proactive about your metabolic health, pru exists to make that smart, informed choice the accessible one: licensed physicians, pharmacy-grade medication, and at-cost pricing in one place. Take the next step when you are ready. See pricing or browse weight loss and metabolism.

Common questions

Is retatrutide better than tirzepatide for weight loss?
In separate trials, retatrutide's top dose produced larger average weight loss, roughly 24% to 29% versus about 20% to 23% for tirzepatide. But these were different studies, not a head-to-head, and retatrutide also had more side effects. It is also not for sale yet, so tirzepatide is the option you can actually use in 2026.
Can I buy retatrutide in 2026?
Not from a legitimate source. Retatrutide is still in clinical trials and is not FDA-approved, so no regulated pharmacy can fill it. Vials sold online as "research-grade" are not made or checked for human use and carry unknown dose and purity.
What is the difference between a triple agonist and a dual agonist?
A dual agonist like tirzepatide switches on two receptors, GLP-1 and GIP, which lower appetite and improve sugar handling. A triple agonist like retatrutide adds a third, glucagon, which may raise how much energy the body burns. More targets is the theory behind retatrutide's larger trial numbers.
When will retatrutide be FDA-approved?
Eli Lilly is expected to file for approval near the end of 2026 after its phase 3 TRIUMPH trials. A typical FDA review takes several months to a year, so approval could land in 2027 or 2028. Timelines can shift.
Do retatrutide and tirzepatide have the same side effects?
Mostly yes. Both cause nausea, vomiting, diarrhea, and constipation, usually strongest after a dose increase and easing over time. Retatrutide's trials reported these more often at higher doses and also noted a small, temporary rise in heart rate.
Does pru offer retatrutide?
No. Retatrutide is investigational, so pru does not offer it and will not point you to grey-market sellers. pru does offer compounded tirzepatide and compounded semaglutide, the GLP-1 options available today, filled by an FDA-regulated 503A pharmacy after a physician confirms fit.
Should I wait for retatrutide or start tirzepatide now?
That is a decision to make with a physician. Tirzepatide has a track record and is available now. Retatrutide's numbers are strong, but there is nothing legitimate to buy yet, so waiting means waiting through 2026 at least.
How does pru keep peptides affordable?
pru runs on an at-cost model. You pay one flat membership, and the medication is passed through at the pharmacy's price with no member markup. Because pru never marks the medication up, we have every reason to push its price down, not up. As pru grows and orders more, we negotiate lower pricing with our partner pharmacies, and those savings go straight to you. Healthcare pricing is usually hidden and inflated; pru is built to sit on your side of it: transparent, at cost, and fighting to make peptides more affordable as we scale.
Do the savings add up if I take more than one peptide?
Yes, and this is where pru's at-cost pricing saves you the most. Because pru never marks the medication up, every vial is priced at cost, so each peptide you add avoids the markup a typical provider builds in. If a physician has you on more than one peptide, or on a stack, that saving repeats on every vial, all under one flat $50 membership instead of a marked-up price on each. The more your protocol includes, the more the difference adds up, which makes doing it the right way a financially responsible choice, not an expensive one.
Sources & further reading
  1. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
  2. https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC12544991/
  4. https://www.kff.org/health-costs/poll-1-in-8-adults-say-theyve-taken-a-glp-1-drug-including-4-in-10-of-those-with-diabetes-and-1-in-4-of-those-with-heart-disease/
  5. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
  6. joinpru.com/shop/product/tirzepatide

Want more like this?

Subscribe to get new articles delivered to your inbox. No spam, unsubscribe anytime.

All Articles

The blog

Stay in the loop.

Evidence-based insights on peptide therapy, longevity, and health optimization, delivered straight to your inbox. No spam, unsubscribe anytime.